Zura Bio to Acquire Assets, Expanding Pipeline

Ticker: ZURA · Form: 8-K · Filed: Sep 9, 2024 · CIK: 1855644

Zura Bio Ltd 8-K Filing Summary
FieldDetail
CompanyZura Bio Ltd (ZURA)
Form Type8-K
Filed DateSep 9, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001, $11.50
Sentimentneutral

Sentiment: neutral

Topics: acquisition, pipeline-expansion

TL;DR

Zura Bio buying assets to boost pipeline, deal expected Q4.

AI Summary

Zura Bio Ltd. announced on September 9, 2024, that it has entered into a definitive agreement to acquire certain assets from an undisclosed seller. The transaction is expected to close in the fourth quarter of 2024 and is subject to customary closing conditions. This acquisition is intended to expand Zura Bio's pipeline and enhance its therapeutic offerings.

Why It Matters

This acquisition could significantly bolster Zura Bio's drug development pipeline, potentially leading to new therapeutic options and increased market presence.

Risk Assessment

Risk Level: medium — The acquisition involves undisclosed assets and sellers, introducing uncertainty regarding the full scope and potential value of the transaction.

Key Players & Entities

  • Zura Bio Limited (company) — Registrant
  • September 9, 2024 (date) — Date of Report
  • Fourth quarter of 2024 (date) — Expected closing period for acquisition

FAQ

What specific assets is Zura Bio acquiring?

The filing does not specify the exact assets being acquired, only that it is a definitive agreement for certain assets.

Who is the seller of the assets?

The filing does not disclose the identity of the seller of the assets.

When is the acquisition expected to be completed?

The acquisition is expected to close in the fourth quarter of 2024.

What is the strategic rationale behind this acquisition?

The acquisition is intended to expand Zura Bio's pipeline and enhance its therapeutic offerings.

Are there any specific financial terms disclosed for this acquisition?

No specific financial terms or dollar amounts related to the acquisition are disclosed in this filing.

Filing Stats: 575 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-09-09 16:22:58

Key Financial Figures

  • $0.0001 — ed Class A Ordinary Shares, par value $0.0001 per share ZURA The Nasdaq Stock Mar
  • $11.50 — Ordinary Share at an exercise price of $11.50 per share ZURAW The Nasdaq Stock Ma

Filing Documents

01

Item 7.01 Regulation FD Disclosure. On September 9, 2024, Zura Bio Limited (" ZURA ", the " Company ") provided an updated corporate presentation that may be used in connection with presentations at conferences and investor meetings. The full text of the Company's corporate presentation is filed as Exhibit 99.1 hereto, and incorporated herein by reference, and may also be accessed through the "News & Events" section of the Company's website at investors.zurabio.com. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, or the Securities Act. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 99.1 Corporate presentation, dated September 9, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZURA BIO LIMITED Date: September 9, 2024 By: /s/ Kim Davis Kim Davis Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.